NovaHep is a biotechnology company founded in 2005 as a spin-off from the Karolinska Institute in Stockholm. As a pioneer within its field, the company has a clear vision to contribute to improve global health, quality of life and cost effective care through introduction of advanced regenerative medicine.
„The future holds bright opportunities for development and delivery of biocompatible tissue-engineered products, and… to imagine… that potentially one day we will be able to engineer entire organs, individualized with the recipient patient’s own stem cells “
With unique, proprietary technology, NovaHep is developing the next generation of tissue-engineered products for vascular replacement therapy. The pipeline of products represent high quality, biocompatible products that are individualized with the patients’ own stem cells. Proof of concept was shown in 2011 (and the results published in medical journal ‘The Lancet’) when, for the first time ever, a tissue-engineered vein was transplanted into a 10-year old girl to replace the portal vein leading blood from the intestines to the liver, giving the girl a whole new life.
Addressing a great, unmet medical need by focusing on hollow and solid organs that are not easily replaced by artificial or semi-artificial prosthetic grafts, NovaHep’s superior biocompatible products avoid the need for lifelong immunosuppression and the need for repeated surgery.
NovaHep – technology with a life-changing impact!
To learn more about NovaHep, please visit www.novahep.com